HD-10991 / Hyundai Pharm - LARVOL DELTA

Discovery of selective SMARCA2 inhibitors for the treatments of SMARCA4 mutated cancers (AACR 2025) - "Additional in vitro and in vivo studies in SMARCA4-mutant cell lines are ongoing to support the further development of these compounds. These findings, highlighting the anti-tumor efficacy and promising drug-like properties of HD-10991 and HD-11030, underscore their potential as candidates for preclinical studies aimed at therapeutic intervention for patients with SMARCA4-mutant cancers."

Lung Cancer • Melanoma • Non Small Cell Lung Cancer • Oncology • Solid Tumor • SMARCA2 • SMARCA4